# 2025-08144: FDA Classifies Non-Bug Infection Spotter Device

2025-08144, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Measure Non-Microbial Analytes To Aid in the Detection and Identification of Localized Human Infections, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08144
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08144
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Measure Non-Microbial Analytes To Aid in the Detection and Identification of Localized Human Infections
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19641
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

FDA Classifies Non-Bug Infection Spotter Device

## Summary

The FDA is officially putting devices that detect and measure non-microbial markers to find localized infections into a safer, more manageable category called Class II. This change, effective May 9, 2025, means these devices will face fewer regulatory hurdles, making it easier and faster for patients to get access to new, helpful infection-detecting tools. Companies making these devices will now follow special safety rules but avoid the toughest approval process, saving time and money.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the device to detect and measure non-microbial analytes to aid in the detection and identification of localized human infections into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the device to detect and measure non-microbial analytes to aid in the detection and identification of localized human infections' classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Faster patient access to new infection tests: benefit, medium. FDA is classifying devices that detect and measure non-microbial markers to help find localized human infections as Class II (special controls), effective May 9, 2025 (classification applicable May 23, 2019). FDA says this classification will reduce regulatory burdens and enhance patients' access t…
- Manufacturers can use 510(k) pathway: benefit, medium. Because FDA has classified this device type into Class II via De Novo, the device can serve as a predicate for future devices and sponsors can use the less-burdensome 510(k) premarket notification process instead of premarket approval. The order codifies the device type at 21 CFR 866.3230 and state…
- Mandatory labeling to prevent misinterpretation: benefit, medium. Manufacturers must include specific labeling under 21 CFR 866.3230, such as a detailed intended use, performance characteristics, interpretation guidance, and limiting statements including that a negative test result does not preclude infection and that results should be interpreted with other clin…
- Required studies, validation, and training for makers: cost, medium. The special controls require manufacturers to provide detailed design descriptions, analytical performance documentation (e.g., limits of detection/quantitation), clinical study data comparing performance to an FDA-accepted reference or comparator, evaluation of analyte levels in asymptomatic patie…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08144 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08144/medical-devices-immunology-and-microbiology-devices-classification-of-the-device-to-detect-and)
- [2025-08144 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08144.pdf)

## Related
- [Previous: 2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA…](https://policyrisk.com/federal-register/2025-08143)
- [Next: 2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Mic…](https://policyrisk.com/federal-register/2025-08145)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08144 (as of 2026-10-16).
